Table 1.
Patient characteristics and treatment in the whole cohort and according to disease size and location
| Whole cohort (N = 683) | Group 1 (n = 269), Dmax <5 cm | Group 2 (n = 274), MB | Group 3 (n = 118), non-MB | Group 4 (n = 22), MB and non-MB | P | |
|---|---|---|---|---|---|---|
| Diameter , cm | ||||||
| <5 | 269 (39.4) | 269 (100) | 0 | 0 | 0 | .000 |
| 5-10 | 278 (40.7) | 0 | 165 (60.2) | 96 (81.4) | 17 (77.3) | |
| 10-15 | 115 (16.8) | 0 | 92 (33.6) | 21 (17.8) | 2 (9.1) | |
| ≥15 | 21 (3.1) | 0 | 17 (6.2) | 1 (0.8) | 3 (13.6) | |
| Sex | ||||||
| Male | 370 (54.2) | 145 (53.9) | 137 (50.0) | 74 (62.7) | 14 (63.6) | .103 |
| Female | 313 (45.8) | 124 (46.1) | 137 (50.0) | 44 (37.3) | 8 (36.4) | |
| Age , y | ||||||
| Median (range) | 34 (15-86) | 41 (15-86) | 28 (15-85) | 42.5 (15-81) | 23.5 (16-58) | .000 |
| Histologic type | ||||||
| NS | 462 (67.6) | 151 (56.1) | 227 (82.8) | 69 (58.5) | 15 (68.2) | .000 |
| MC | 111 (16.3) | 59 (21.9) | 21 (7.7) | 27 (22.9) | 4 (18.2) | |
| LR | 10 (1.5) | 8 (3.0) | 2 (0.7) | 0 | 0 | |
| LD | 8 (1.2) | 2 (0.7) | 4 (1.5) | 2 (1.7) | 0 | |
| Unclassified | 92 (13.5) | 49 (18.2) | 20 (7.3) | 20 (16.9) | 3 (13.6) | |
| CD20 | ||||||
| Positive | 93 (13.6) | 41 (15.2) | 32 (11.7) | 16 (13.6) | 4 (18.2) | .565 |
| Negative | 507 (74.2) | 194 (72.1) | 207 (75.5) | 88 (74.6) | 18 (81.8) | |
| UK | 83 (12.2) | 34 (12.6) | 35 (12.8) | 14 (11.9) | 0 | |
| BM | ||||||
| Positive | 82 (12.0) | 45 (16.7) | 10 (3.6) | 26 (22.0) | 1 (4.5) | .000 |
| Negative | 567 (83.0) | 211 (78.4) | 252 (92.0) | 85 (72.0) | 19 (86.4) | |
| UK | 34 (5.0) | 13 (4.8) | 12 (4.4) | 7 (5.9) | 2 (9.1) | |
| ECOG PS * | ||||||
| 0 | 361 (55.4) | 143 (57.0) | 151 (57.6) | 58 (49.2) | 9 (42.9) | .058 |
| 1 | 250 (38.3) | 86 (34.3) | 101 (38.5) | 51 (43.2) | 12 (57.1) | |
| ≥2 | 41 (6.3) | 22 (8.8) | 10 (3.8) | 9 (7.6) | 0 | |
| UK | 31 | 18 | 12 | 0 | 1 | |
| B symptoms * | ||||||
| No | 311 (45.6) | 133 (49.6) | 126 (46.0) | 45 (38.1) | 7 (31.8) | .132 |
| Yes | 362 (53.1) | 129 (48.1) | 146 (53.3) | 72 (61.0) | 15 (68.2) | |
| UK | 10 (1.3) | 7 (2.3) | 2 (0.7) | 1 (0.8) | 0 | |
| Spleen * | ||||||
| Positive | 236 (35.2) | 85 (32.9) | 89 (32.7) | 52 (44.1) | 10 (45.5) | .094 |
| Negative | 434 (64.8) | 173 (67.1) | 183 (67.3) | 66 (55.9) | 12 (54.5) | |
| UK | 13 | 11 | 2 | 0 | 0 | |
| Liver * | ||||||
| Positive | 73 (10.9) | 32 (12.4) | 26 (9.6) | 15 (12.7) | 0 | .241 |
| Negative | 597 (89.1) | 226 (87.6) | 246 (90.4) | 103 (87.3) | 22 (100) | |
| UK | 13 | 11 | 2 | 0 | 0 | |
| Lung * | ||||||
| Positive | 167 (24.9) | 49 (19.0) | 88 (32.4) | 24 (20.3) | 6 (27.3) | .003 |
| Negative | 503 (75.1) | 209 (81.0) | 184 (67.6) | 94 (79.7) | 16 (72.7) | |
| UK | 13 | 11 | 2 | 0 | 0 | |
| Bone * | ||||||
| Positive | 213 (31.8) | 84 (32.6) | 76 (27.9) | 45 (38.1) | 8 (36.4) | .228 |
| Negative | 457 (68.2) | 174 (67.4) | 196 (72.1) | 73 (61.9) | 14 (63.6) | |
| UK | 13 | 11 | 2 | 0 | 0 | |
| Stage | ||||||
| III | 303 (44.4) | 123 (45.7) | 119 (43.4) | 52 (44.1) | 9 (40.9) | .938 |
| IV | 380 (55.6) | 146 (54.3) | 155 (56.6) | 66 (55.9) | 13 (59.1) | |
| IPS * | ||||||
| 0-1 | 176 (26.1) | 75 (28.3) | 65 (24.0) | 28 (23.9) | 8 (36.4) | .159 |
| 2-3 | 343 (50.8) | 125 (47.2) | 154 (56.8) | 55 (47.0) | 9 (40.9) | |
| 4-6 | 156 (23.1) | 65 (24.5) | 52 (19.2) | 34 (29.1) | 5 (22.7) | |
| UK | 8 | 4 | 3 | 1 | 0 | |
| Treatment | ||||||
| Chemo | 533 (78.0) | 238 (88.5) | 182 (66.4) | 98 (83.1) | 15 (68.2) | .000 |
| CMT | 150 (22.0) | 31 (11.5) | 92 (33.6) | 20 (16.9) | 7 (31.8) | |
| Chemo regimen | ||||||
| ABVD | 530 (77.6) | 203 (74.4) | 202 (73.7) | 108 (91.5) | 17 (77.3) | .022 |
| Stanford V | 21 (3.1) | 6 (2.2) | 14 (5.1) | 0 | 1 (4.5) | |
| BEACOPP | 67 (9.8) | 28 (10.4) | 32 (11.7) | 4 (3.4) | 3 (13.6) | |
| BEACOPP + ABVD | 35 (5.1) | 17 (6.3) | 15 (5.5) | 2 (1.7) | 1 (4.5) | |
| Other | 30 (4.4) | 15 (5.6) | 11 (4.0) | 4 (3.4) | 0 |
Data are expressed as n or n (%), unless otherwise noted.
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BM, bone marrow; Chemo, chemotherapy; CMT, combined modality treatment; Dmax, maximal diameter; LD, lymphocyte depleted; LR, lymphocyte predominant; MC, mixed cellularity; NA, not available; PS, performance status; UK, unknown.
*
Missing values account for <5% and were thus not analyzed.